Panorama epidemiológico y clínico de la cardiopatía chagásica crónica en México

Sierra‐Johnson, Justo; Olivera-Mar, Amonario; Monteón-Padilla, Víctor Manuel; Reyes, Pedro A.; Vallejo, Maité

doi:10.1590/s0034-89102005000500009

Cited by 11 publications

(9 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two relevant studies in Mexico analyze the prevalence of CC on CD. One of them was carried out from 1977 to 1988 at the national institute of cardiology Ignacio Chávez, a heart disease center in Mexico City, where a prevalence of 8% was found 9 , this was a retrospective study, the other one was performed in the same heart disease center, in a prospective study from 1993 to 2003, with a prevalence of 40%, in this study the population was from central and southeastern states of the country 10 . However, in studies with small samples and short analysis periods, surprisingly high prevalence is found, which reach 82.5%, these reports correspond mainly to rural populations with extreme poverty in the southeast of Mexico 27 - 29 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalencia de cardiopatía chagásica en la miocardiopatía dilatada

González-Zambrano¹,

Amaya-Tapia²,

Franco-Ramos³

et al. 2021

ACM

View full text Add to dashboard Cite

Objectives:The main objective is to determine the prevalence of American trypanosomiasis in patients with dilated cardiomyopathy in a tertiary hospital in western Mexico. Methods: From January 1991 to February 2016, 387 consecutive patients with a confirmed diagnosis of dilated cardiomyopathy were included in the study. Cases with ventricular dilatation secondary to ischemic heart disease, valvular heart disease, hypertension, lung disease, pericardial disease, or congenital heart disease were excluded from the study. Diagnosis was made detecting antibodies against Trypanosoma cruzi with two different methods or parasite in blood. Results: Were included 387 patients with dilated cardiomyopathy, Chagas cardiomyopathy was confirmed in 6.9%, two patients in the acute phase (in one, suspected transfusion transmission was detected). Most patients were born in rural areas. About 96.2% showed congestive heart failure, only one patient with apical left ventricular aneurysm manifested palpitations. About 66% with right bundle branch block, left anterior fascicular block, or the association of both, in 14.8%, non-sustained ventricular tachycardia was found. Conclusions: Chagas cardiomyopathy is common in México, mainly in people who were born or lived during childhood in rural areas. It is a common cause of heart failure. Chagas' heart disease should be suspected in patients receiving a blood transfusion, even without another epidemiological history.

show abstract

Section: Discussionmentioning

confidence: 99%

“…According to estimates from the World Health Organization, Mexico is currently considered within the countries with a seroprevalence that ranges from 0.1 to 0.9% 8 . In large studies in México, the prevalence of CC in patients with dilated cardiomyopathy (DC) is from 8 to 40% 9 , 10 .…”

Section: Introductionmentioning

confidence: 99%

Prevalencia de cardiopatía chagásica en la miocardiopatía dilatada

González-Zambrano¹,

Amaya-Tapia²,

Franco-Ramos³

et al. 2021

ACM

View full text Add to dashboard Cite

show abstract

“…Chagas disease is the leading cause of complete atrioventricular block in areas where the disease is endemic; 31 it was found in about 10 % of patients seen in one referral centre for the treatment of Chagas disease. 32 In other referral centres specialised in heart failure treatment, however, the frequency of pacemakers in patients with Chagas heart failure is as high as 50 %. 33 The presence of CHF and advanced atrioventricular block in young patients from an endemic area should therefore alert the physician to a diagnosis of Chagas cardiomyopathy.…”

Section: Peculiarities Of Subsidiary Testsmentioning

confidence: 99%

Chagas Heart Failure in Patients from Latin America

Bestetti

2016

Cardiac Failure Review

View full text Add to dashboard Cite

Physicians working in Europe and the United States should suspect Chagas heart failure in every patient coming from Latin America with chronic heart failure. Diagnosis should be confirmed by positive serology. Right bundle branch block and left anterior fascicular block on 12-lead electrocardiogram, enlarged cardiac silhouette with no pulmonary congestion on chest X-ray and left ventricular apical aneurysm on echocardiography are the distinctive features of this condition. The clinical course is poorer than that of non-Chagas heart failure; however, medical treatment is similar. Implantable cardioverter-defibrillators are useful in the primary and secondary prevention of sudden cardiac death. Cardiac resynchronisation therapy can be given to patients on optimal medical therapy and with lengthened QRS complex. Heart transplantation is the treatment of choice for patients with end-stage Chagas heart failure.

show abstract

“…La cardiomiopatía chagásica crónica podría estar afectando a individuos con enfermedad cardiaca, aún cuando los casos no se reportan debido a la ausencia de especificidad del cuadro clínico (2). Diversos estudios muestran que la cardiopatía chagásica crónica en México es una causa común de la miocardiopatía dilatada, debido a su distribución regional y merece atención (1). En el Estado de Campeche, se observa serología positiva para Tripanosoma cruzi en pacientes con diagnóstico clínico de miocardiopatía dilatada del orden del 15% (3).…”

Section: Abstract Hearth Transplants For Chagas Disease In Mexicounclassified

El trasplante cardiaco por enfermedad de Chagas en México

Lozano-Kasten¹,

Soto-Gutiérrez²,

Magallón-Gastelúm³

et al. 2015

Rev Biomed

View full text Add to dashboard Cite

El objetivo de este escrito, es presentar los datos clínicos, quirúrgicos, paraclínicos, terapeúticos, y epidemiológicos que sustentan la existencia del primer caso de trasplante cardíaco por cardiopatía chagásica en México. Se trata de un paciente masculino de 35 años de edad, al que se realizó trasplante cardiaco por cardiomiopatia dilatada no compatible con la vida; comprobado por serología y aislamiento del T. cruzi posterior a la intervención quirúrgica realizada al presentar complicaciones posteriores al trasplante. A 9 años del trasplante, el paciente se considera curado y reintegrado al trabajo. Los pacientes diagnosticados clínicamente con miocardiopatía dilatada y serología positiva a T cruzi, son frecuentes, en el orden de 15% en el país. La presencia del presente caso y la circunstancia en que se diagnosticó, orienta la existencia de un mayor número de casos ya trasplantados y no diagnosticados en el país. Por lo tanto, es necesario reconocer en pacientes candidatos a trasplante cardiaco por miocardiopatía dilatada, la enfermedad de Chagas.

show abstract

Panorama epidemiológico y clínico de la cardiopatía chagásica crónica en México

Cited by 11 publications

References 5 publications

Prevalencia de cardiopatía chagásica en la miocardiopatía dilatada

Prevalencia de cardiopatía chagásica en la miocardiopatía dilatada

Chagas Heart Failure in Patients from Latin America

El trasplante cardiaco por enfermedad de Chagas en México

Contact Info

Product

Resources

About